相关实验视频
Updated: Jun 21, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
人工甜味剂及其对糖尿病的影响:一篇综述
Matcha Angelin1, Janardhanan Kumar2, Leela Kakithakara Vajravelu1
1Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM IST, Kattankulathur, Tamil Nadu, India.
Frontiers in nutrition
|July 11, 2024
概括
人工甜味剂 (ASs) 可能有助于控制糖尿病,帮助控制体重,而不会影响血糖. 然而,它们对肠道微生物群和胰岛素敏感性的影响需要进一步研究.
科学领域:
- 营养科学 营养科学
- 代谢健康 代谢健康
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病是一种主要的全球健康问题.
- 饮食策略对于糖尿病管理和预防至关重要.
- 人工甜味剂 (ASs) 提供无卡路里的甜味,为糖尿病管理提供了潜在的工具.
研究的目的:
- 审查人工甜味剂和糖尿病之间的复杂关系.
- 评估ASS在糖尿病管理中的益处和潜在风险.
- 突出了对ASs代谢影响的进一步研究的需要.
主要方法:
- 关于人工甜味剂和糖尿病现有研究的文献综述.
- 分析AS对体重管理,血糖水平和肠道微生物群的影响.
- 检查有关胰岛素敏感性和耐药性的相互矛盾的发现.
主要成果:
- AS可以帮助控制体重,这是预防糖尿病的关键因素.
- ASs不会急性影响血糖水平,可能会改善血糖控制.
- AS可能与肠道微生物群相互作用,对代谢健康和胰岛素敏感性产生潜在影响,尽管研究结果相互矛盾.
结论:
- 要了解AS在糖尿病管理中的作用,必须采用细微的方法.
- 混合证据需要进一步研究ASs对代谢健康的影响.
- 作为糖尿病饮食干预的一部分,ASs的适用性仍在调查中.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
169
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
169
Oral Hypoglycemic Agents: Sulfonylureas
199
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
199
Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152

